臨床外科68巻8号

2013年08月発行

特集 外科医のための癌免疫療法―基礎と臨床 基礎編

癌免疫療法の基礎

著者： 河上裕¹

所属機関： ¹慶應義塾大学医学部先端医科学研究所細胞情報研究部門

ページ範囲：P.886 - P.893

【ポイント】

◆がんは形成過程で免疫抵抗性を獲得し，がん患者では多様な免疫細胞や分子が関与する免疫抑制環境が構築されている．

◆最近の臨床試験で治療効果が認められ，今後，免疫療法は「効果が期待できる症例では長期延命をもたらす治療」となることが期待されている．

◆効果が期待できる症例を選択するバイオマーカーの同定や，抗腫瘍免疫ネットワークの制御による強力な複合免疫療法の開発が進められている．

参考文献

1）Schreiber RD, Old LJ, Smyth, MJ, Cancer Immunoediting：Integrating Immunity's Roles in Cancer Suppression and Promotion. Science 331：1565-1570, 2011

2）河上　裕：腫瘍免疫．谷口　克（監修），宮坂昌之，小安重夫（編）：標準免疫学 第3版，医学書院，2013

3）Kawakami Y, Fujita T, Matsuzaki Y, et al：Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95：784-791, 2004

4）Robbins PF, Lu YC, El-Gamil M, et al：Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med, 2013［Epub ahead of print］

5）Zitvogel L, Kepp O, Kroemer G：Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8：151-160, 2011

Shurin MR, Umansky V, Malyguine A（eds）：The Tumor Immunoenvironment. Springer, 2013, pp307-323

7）Yaguchi T, Sumimoto H, Kudo-Saito C, et al：The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 93：294-300, 2011

8）Fridman WH, Pagès F, Sautès-Fridman C, et al：The immune contexture in human tumours：impact on clinical outcome. Nat Rev Cancer 12：298-306, 2012

9）Galon J, Pagès F, Marincola FM, et al：Cancer classification using the Immunoscore：a worldwide task force. J Transl Med 10：205, 2012

10）Taube JM, Anders RA, Young GD, et al：Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4：127, 2012

11）Lurquin C, Lethé B, De Plaen E, et al：Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201：249-257, 2005

12）Hodi FS, O' Day SJ, McDermott DF, et al：Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363：711-723, 2010

13）Topalian SL, Hodi S, Brahmer JR, et al：Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366：2443-2454, 2012

14）Schwartzentruber DJ, Lawson DH, Richards JM, et al：gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364：2119-2127, 2011

15）Rosenberg SA, Yang JC, Sherry RM, et al：Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17：4550-4557, 2011

16）Robbins PF, Morgan RA, Feldman SA, et al：Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29：917-924, 2011

17）Kalos M, Levine BL, Porter DL, et al：T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3：95, 2011

18）Couzin-Frankel J：Immune therapy steps up the attacks. Science 330：440-443, 2010

19）Kawakami Y, Yaguchi T, Sumimoto H, et al：Improvement of cancer immunotherapy by combining molecular targeted therapy. Front Oncol 3, 2013

20）Wilmott JS, Long GV, Howle JR, et al：Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18：1386-1394, 2011

21）Ueda R, Ohkusu-Tsukada K, Fusaki N, et al：Identification of HLA-A2-and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer 126：919-929, 2010

22）Udagawa M, Kudo-Saito C, Hasegawa G, et al：Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin Cell Wall Skeleton Stimulation. Clin Cancer Res 12：7465-7475, 2006

23）Sumimoto H, Imabayashi F, Iwata T, et al：The BRAF-MAPK signaling pathway is essential for cancer immune evasion in human melanoma cells. J Exp Med 203：1651-1656, 2006

24）Wolchok JD, Hoos A, O' Day S, et al：Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors：Immune-Related Response Criteria. Clin Cancer Res 15：7412-7420, 2009

25）FDA Guidance for Industry Clinical Considerations for Therapeutic Cancer Vaccines（http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf）